Fierce Healthcare

JANUARY 23, 2023

Amazon Pharmacy rolls out service for unlimited generic drug prescriptions for $5 a month hlandi Mon, 01/23/2023 - 22:15

145

145

Pharmafile

JANUARY 23, 2023

Indian biotech company Bharat Biotech plans to launch its new intranasal COVID-19 vaccine iNCOVACC on the 26 January 2023 ‒ the vaccine is the first of its kind to be developed in India. read more Medical Communications

Vaccines 98

Vaccines Communication 98

Pharma Phorum

JANUARY 23, 2023

Run by Life Science Integrates, Pharma Integrates was in its 11th year in 2022.

98

98

European Pharmaceutical Review

JANUARY 23, 2023

The US Food and Drug Administration (FDA) has granted fast track designation (FTD) for Evaxion Biotech’s personalised cancer immunotherapy. The FTD is for EVX-01, in combination with Keytruda ® for patients with metastatic melanoma (MM). ”We

Immunization 119

Immunization Vaccines FDA 119

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

This webinar will go over the FDA's guidance on pharmacological and toxicological considerations for optimizing doses for prescription drugs.

Dosage

Fierce Healthcare

JANUARY 23, 2023

Man Therapy brings effective digital mental health support to the population most likely to commit suicide, CDC study finds aburky Mon, 01/23/2023 - 17:10

111

111

Pharmaceutical Technology

JANUARY 23, 2023

Systemic lupus erythematosus (SLE) is a systemic, inflammatory, chronic autoimmune disease that can affect multiple organs simultaneously or sequentially, with a relapsing and remitting nature.

Labelling 111

Labelling Immunization 111

Fierce Healthcare

JANUARY 23, 2023

CMMI Director Liz Fowler: Expect advance primary care, total cost models to be released in 2023 rking Mon, 01/23/2023 - 16:37

105

105

Outsourcing Pharma

JANUARY 23, 2023

The company plans to conduct a Phase 2b trial to test its APEX-52 psilocybin drug candidate to treat adults with post-traumatic stress disorder. Clinical Development

97

97

Fierce Healthcare

JANUARY 23, 2023

Substance use disorders cost employer-sponsored health insurance over $35B a year: CDC study fdiamond Mon, 01/23/2023 - 16:36

Insurance 105

Insurance 105

Pharmafile

JANUARY 23, 2023

The FDA has granted Breakthrough Device Designation for US-based medical technology company CardioRenal for their RenalGuard Therapy device, used to treat a kind of kidney disease.

FDA 64

FDA Communication 64

Fierce Healthcare

JANUARY 23, 2023

Elevance Health to acquire Blue Cross and Blue Shield of Louisiana pminemyer Mon, 01/23/2023 - 17:09

105

105

European Pharmaceutical Review

JANUARY 23, 2023

The European Commission (EC), European Medicines Agency (EMA), and the Heads of Medicines Agencies (HMA), through the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) , are closely monitoring and responding to current antibiotic shortages in the EU.

Packaging 91

Packaging Compounding Labelling Communication 91

Fierce Healthcare

JANUARY 23, 2023

Lawmaker-backed report accuses UPMC of 'anti-competitive' monopoly, calls for policy intervention dmuoio Mon, 01/23/2023 - 11:14

98

98

Fierce Pharma

JANUARY 23, 2023

Takeda pledges up to $1.13B for rights to Hutchmed's cancer drug fruquintinib outside of China kdunleavy Mon, 01/23/2023 - 09:49

85

85

Fierce Healthcare

JANUARY 23, 2023

CVS taps key pharmacy services, consumer products execs: report pminemyer Mon, 01/23/2023 - 13:32

85

85

Pharma Mirror

JANUARY 23, 2023

The White House Office of Science & Technology Policy (OSTP) convened a listening session January 11.

Vaccines 59

Vaccines 59

Pharma Phorum

JANUARY 23, 2023

Motion capture technology used to bring fantasy characters to life in movies like Avatar and The Lord of the Rings is being used alongside artificial intelligence (AI) to track diseases that lead to disorders of movement.

59

59

Fierce Pharma

JANUARY 23, 2023

Bayer chairman under fire for lack of spinoff activity amid renewed investor activism aliu Mon, 01/23/2023 - 09:46

81

81

European Pharmaceutical Review

JANUARY 23, 2023

Data from a Phase III trial evaluating a regimen of Onivyde ® (irinotecan liposome injection), in previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC) demostrated significant improvements in patient survival.

Chemotherapy 80

Chemotherapy Labelling FDA 80

Fierce Pharma

JANUARY 23, 2023

Big Pharma set for more Senate scrutiny as Democrats eye pricing, tax probes: report fkansteiner Mon, 01/23/2023 - 14:30

74

74

Pharmaceutical Commerce

JANUARY 23, 2023

Creates Cellular Origins in order to simplify the late-stage development process us

52

52

PharmExec

JANUARY 23, 2023

"AH-ha!™ It's Acne Hormones" features people affected by acne and highlights "AH-ha" moments to "pop" common acne myths and misconceptions.

52

52

Pharma Phorum

JANUARY 23, 2023

Jazz Pharma’s $325 million gamble on rights to Zymeworks’ HER2-directed bispecific antibody zanidatamab was the largest in its history, and seems like a safer bet after a mid-stage readout at the ASCO-GI 2023 congress.

Chemotherapy 52

Chemotherapy Labelling 52

Pharmafile

JANUARY 23, 2023

A team of researchers have been developing a monitoring system to assess the progression of movement disorders. The new technology utilises motion capture technology and AI. read more Research and Development

52

52

Pharma Phorum

JANUARY 23, 2023

Ipsen and partner Servier hope to extend the uses of their pancreatic cancer therapy Onivyde into the first-line treatment setting, assisted by new phase 3 data reported at the ASCO-GI 2023 congress.

52

52

Pharmafile

JANUARY 23, 2023

Seagen Inc has been given FDA Accelerated Approval for its colorectal drug TUKYSA (tucatinib) after reviewing positive data from the MOUNTAINEER phase 2 trial.

Chemotherapy 52

Chemotherapy FDA 52

Pharma Phorum

JANUARY 23, 2023

Beijing-based pharma, BeiGene’s Brukinsa (zanubrutinib) has been approved by the US Food and Drug Administration (FDA) for chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL). CLL is a common form of leukaemia and accounts for roughly 25% of all new cases each year.

Adverse Reactions 52

Adverse Reactions FDA Dosage 52

Pharmafile

JANUARY 23, 2023

Compounding 52

Compounding 52

Pharma Phorum

JANUARY 23, 2023

Chinese biotech Hutchmed’s push to sign partnerships for its drug products outside its home market has resulted in a $1.13 billion deal with Japan’s Takeda, including a hefty upfront fee of $400 million.

FDA 52

FDA 52

Pharmafile

JANUARY 23, 2023

Published date: 23/01/2023 Summary: STOCKHOLM, SWEDEN – 23 January 2023: Modus Therapeutics AB (“Modus”), a company developing innovative treatments for patients with major unmet medical needs, announces that it has submitted a patent application claiming the use of sevuparin, its lead asset, for the treatment of kidney disease.

52

52

Pharma Phorum

JANUARY 23, 2023

Morphic Therapeutic has lost Johnson & Johnson’s Janssen Pharma as a partner, following the termination of an alliance to develop drugs targeting integrins first agreed in 2019. In a filing with the Securities and Exchange Commission (SEC).

Compounding 52

Compounding FDA 52

PharmaVoice

JANUARY 23, 2023

Cultivate relationships with HCPs in gated social platforms with content that will thrive

52

52

Roots Analysis

JANUARY 23, 2023

Monkeypox is a viral disease, which is usually transmitted to humans from animals. The disease is known to have symptoms similar to those observed in smallpox patients, although it is considered to be clinically less severe.

Vaccines 52

Vaccines 52

PharmaVoice

JANUARY 23, 2023

As the CMS readies its new program for lowering drug costs, these are the moments that will matter most to pharma companies

52

52

Pharmacy Times

JANUARY 23, 2023

A recent study shows that heart patients who learn to cope with stress in group therapy are nearly 2 times less anxious and depressed.

65

65

PharmaVoice

JANUARY 23, 2023

With two potential first-in-class drug launches on the horizon, and a budding gene therapy business, Astellas believes this year could be a major inflection point

52

52